Development and in-vitro evaluation of candy based medicated lollipops: a novel system of drug delivery by Rathod, Minakshi et al.
Rathod et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2018; 8(4):196-204           
ISSN: 2250-1177                                                                             [196]                                                                             CODEN (USA): JDDTAO 
Available online on 15.07.2018 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-
commercial use, provided the original work is properly cited 
Open  Access                                                                                                                     Research Article 
DEVELOPMENT AND IN-VITRO EVALUATION OF CANDY BASED 
MEDICATED LOLLIPOPS: A NOVEL SYSTEM OF DRUG DELIVERY 
Minakshi Rathod
*
, Sandesh Sul, Sachin Poharkar, Yuvraj Pandhare, Monali Muneshwar 
MUP’S Institute of Pharmacy (D.PHARM), Pundlik Nagar Degaon, Tq-Risod Dist-Washim (444506) M.H., India 
 
ABSTRACT 
Lollipops or lozenges are defined as the flavored medicated dosage forms intended to be sucked and held in the mouth or pharynx 
containing one or more medicaments usually in the sweetened base. Lollipops are commonly used for the purpose of local or 
systemic effects through the buccal mucosa. Advantages of the lollipop as dosage forms include increase in bioavailability, reduction 
in dose size, gastric irritation and bypass first metabolism1. Lollipop is designed to improve patient compliance, acceptability, 
transportation etc2The lollipops were prepared by heating and congealing method in a candy based industry with sucrose base. All 
the formulations prepared were subjected to various physicochemical parameters like hardness, content uniformity, friability, weight 
variation etc. Thickness of lollipop ranges from 12-13.2 mm. The hardness of these lollipops ranges between 10-11.5 kg/cm... 
Results of in-vitro release profile indicated that formulation L3, L6, and L10 were the most promising formulations as the extent of 
drug release from this formulation was high as compare to other formulations up to 30 mins. The in vitro release of medicated 
lollipop of ambroxol HCl was found in the release of drug from the lollipop depends on the type and concentration of polymer used. 
As per all satisfactory evaluation parameters, the batch L3 is found to be optimized batch. The stability studies showed that there was 
no change in the formulation after 90 days. The medicated lollipops can provide an attractive alternative formulation in the treatment 
of mucolytics in pediatric patients. 
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INTRODUCTION 
Lollipops or lozenges are defined as the flavoured 
medicated dosage forms intended to be sucked and held 
in the mouth or pharynx containing one or more 
medicaments usually in the sweetened base. Lollipops 
are commonly used for the purpose of local or systemic 
effects through the buccal mucosa. Advantages of the 
lollipop as dosage forms include increase in 
bioavailability, reduction in dose size, gastric irritation 
and bypass first metabolism
1
. Lollipop is designed to 
improve patient compliance, acceptability, 
transportation etc 
2,3
. For the past two decades, there has 
been an enhanced demand for more patient compliance 
dosage forms. As a result, the demand for their 
technologies has been increasing three-fold annually. 
Since the development cost of a new chemical entity is 
very high, the pharmaceutical companies are now 
focusing on the development of new drug delivery 
systems for existing drug with an improved efficacy and 
bioavailability together with reduced dosing frequency 
to minimize side effects
4
. The advantages of this 
formulation are easy to administer to both paediatric as 
well as geriatric patients and Systemic absorption of 
drugs can be possible through buccal cavity. Drug 
candidates which can be incorporated in lollipop, belong 
to one of the following categories: Antiseptics, Local 
anaesthetics, Antibiotics, Antihistaminics, Antitusives, 
Analgesics, Decongestant, Antifungal. 
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Classification of lozenges  
Lozenges can be classified into various classes based on 
various methods like 
(A) According to the site of action 
       (a) Local effect 
            Ex. Antiseptics, Decongestants. 
      (b) Systemic effect 
            Ex. Vitamins, Nicotine. 
(B) According to texture and composition 
       (a) Chewy or caramel based medicated Lozenges 
       (b) Compressed tablet lozenges 
       (c) Soft lozenges  
       (d) Hard lozenges 
Hard Candy Lozenges or lollipop: 
Hard candy lozenges are mixtures of sugar and other 
carbohydrates in an amorphous (noncrystalline) or 
glassy state. They can also be regarded as solid syrups 
of sugars. The moisture content and weight of hard 
candy lozenge should be between, 0.5 to 1.5% and 1.5-
4.5g respectively. These should undergo a slow and 
uniform dissolution or erosion over 5-10min., and 
should not disintegrate. The temperature requirements 
for their preparation is usually high hence heat labile 
materials cannot be incorporated in them
5,6
. The 
ingredients for hard candy lozenges include body agent 
or base which is corn syrup that is available on Baume 
basis. A 43° Baume corn syrup is preferred in hard 
candy lozenges. Sweetening agents such as sucrose, 
dextrose, maltose and lactose are added. Acidulents are 
added to candy base to strengthening the flavor 
characteristics of the finished product. Commonly used 
acids are citric, tartaric, fumaric and malic acid. Colours 
include FD & C colours, orange colour paste, red colour 
cubes etc while flavours used include menthol, 
eucalyptus oil, spearmint, cherry flavor etc. 
Medicaments up to 2-4% can be incorporated in the hard 
candy lozenges. Salvage solution can be liquid or solid5. 
METHODS 
Preformulation Studies of Drug 
7 
Preformulation can be defined as investigation of 
physical and chemical properties of drug substance 
alone and when combined with excipients. 
Preformulation studies are the first step in the rational 
development of dosage form of a drug substance. The 
goals of the program therefore are To establish the 
necessary physicochemical characteristics of a new drug 
substance. To establish its compatibility with different 
excipients.  
Characterization of Ambroxol HCL: 
Organoleptic properties 
8
 
The drug powder was analyzed for color, odor and taste. 
 Description 
8
 
The drug sample (Ambroxol HCl ) was analyzed for 
physical appearance and powder nature. 
 Melting point 
8
 
Melting point determination of Ambroxol HCl was done 
by open capillary method. It is a good first indication of 
purity of sample since the presence of relatively small 
amount of impurity can be detected by a lowering as 
well as widening of melting point range. 
Solubility Characteristics 
A semi quantitative determination of solubility can be 
made by adding a solute in small incremental amount to 
fixed volume of solvents, phosphate buffer pH 6.8, 
sparingly soluble in water, soluble in methanol, 
practically insoluble in methylene chloride. After each 
addition, the system is vigorously shaken and examined 
usually for any undissolve particles 
Spectroscopy 
UV-visible Spectroscopy
9 
Determination of λ max 
The UV absorption spectrum of Ambroxol HCL was 
obtained using a UV-visible Spectrophotometer. The 
spectrum was scanned from 200 nm to 400 nm. A 
typical spectrum of Ambroxol HCl dissolved in 
phosphate buffer 6.8 (Conc. 100µg/ml) is shown in fig 
2. 
Preparation of Standard Stock Solution 
Standard stock solution of Ambroxol Hydrochloride 
were prepared by dissolving 10 mg of AMB separately 
in 10 ml of 6.8 pH Phosphate buffer solution and 
sonicated for 15 minutes and filtered through whatman 
filter paper in order to get dilution of 1 mg/1 ml i.e.1000 
μg/ml. 
Determination of Absorption Maximas 
By appropriate dilution of standard stock solutions of 
Ambroxol Hydrochloride with 6.8 pH phosphate buffer 
solution containing and 10 μg/ml of Ambroxol 
Hydrochloride was scanned separately in the range of 
200-400nm. Wavelength of absorption maxima was 
determined for drugs. Ambroxol HCL showed 
absorption maxima one at 245 nm. 
Preparation of calibration curve for Ambroxol HCL 
Concentration was made using the phosphate buffer pH 
6.8 media. It was analyzed spectrophotometrically by 
measuring the absorbance at 245 nm wavelength. The 
fig 1 shows standard calibration curves with slope 0.026 
and regression value 0.9999. The curve was found to be 
linear in the range 2-18 μg/ml at .the drug solution of 
with concentration of 100μg/ml was prepared. Serial 
dilution 2, 4....18μg/ml 
IR Spectroscopy 
The IR spectrum of drug & excipients was obtained in a 
KBR pellet using Shimadzue 206-7350038 FT-IR 
spectrophotometer. FT-IR spectra were recorded in the 
region of 400–4,000 cm-1. Assign the major absorption 
bands change in absorption bands indicates 
incompatibility between drug & excipients. 
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Formulation of medicated lollipop:
Table 1: Formulation table for medicated lollipop 
Ingredients 
In mg 
L0 L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 
Ambroxol HCl 15 15 15 15 15 15 15 15 15 15 15 
Sucrose 3523 3490 3465 3440 3490 3465 3440 3465 3440 3465 3440 
Dextrose 1420 1420 1420 1420 1420 1420 1420 1420 1420 1420 1420 
Citric acid 50 50 50 50 50 50 50 50 50 50 50 
Methyl cellulose - 25 50 75 - - - - - - - 
Scmc - - - - 25 50 75 - - - - 
Hpmc k100m - - - - - - - 50 75 - - 
Hpmc k4 m - - - - - - - - - 50 75 
Colouring agent  Quantity sufficient 
Flavouring agent  Quantity   sufficient 
PurifiedH2O Quantity  sufficient 
 
Preparation of syrup base: 
Syrup base was prepared by dissolving 66.66%w/v 
sucrose in purified water at 110
o
c and continuously 
stirring for about 90 min.  
Preparation of medicated Lollipops
10
: 
Medicated lollipops of 5 gms were prepared. The 
Method followed for the preparation was heating and 
congealing technique. Syrupy base was prepared in a 
beaker dissolving the required amounts of sucrose in 
water on heating and stirring at 110°C for about 90 min. 
Dextrose was added and stirring continued for 2 hrs by 
raising the temperature to 160°C. The material was 
transferred to a cooling slab and temperature was 
brought down 90°C till a plastic mass was obtained. 
Drug, polymer, colour, flavour were added and mixed 
the material for 30 min. The material was size roped on 
moving rollers which were then sized into 5gms. 
Lollipops and air dried for about 2 hrs. in drying 
chamber. The prepared lollipops were seal wrapped in 
polythene wrappings. An altogether three batches of 
formulations were prepared i.e., without added 
hydrocolloid, hydroxy propyl methyl cellulose (HPMC) 
K4M and K100M, methyl cellulose, carboxy methyl 
cellulose sodium salt added medicated lollipops. 
 RESULTS AND DISCUSSION 
Characterization of Ambroxol HCl 
Organoleptic characterization and Melting point 
determination 
The physicochemical characteristics of Ambroxol HCL 
are described in Table 2. 
Table 2: Physicochemical Characteristics of 
Ambroxol HCL. 
Sr. no. Test Observation 
1. Colour White to yellowish 
crystalline powder 
2. Odour Odourless 
3. Taste Bitter 
5. Melting point 233-234.5 
6. pH 4.5-6.0 
 
The organoleptic character and melting point was found 
to be as per standard drug so drug used in the 
formulation was found to be pure according to I.P. 
specification. 
Solubility analysis: 
Table 3: Solubility profile of Ambroxol HCl 
Sr. No. Solvent Solubility 
1. 1. Water Sparingly soluble 
2. 2. Buffer solution 6.8  Soluble 
3. 3. Methanol      Soluble 
 
The solubility of pure drug in 10mg/10ml of solvent was 
carried out and it reveals that it is soluble in methanol, 
sparingly soluble in water, soluble in phosphate buffer 
ph 6.8. 
Standard calibration curve of ambroxol HCL in 
phosphate buffer 6.8: 
 
Figure 1: Calibration curve of ambroxol HCl in pH 
6.8 
Determination of λmax:  
The UV spectrum of ambroxol HCL in phosphate buffer 
6.8 showed maximum absorption at 245 nm. Hence drug 
used in the formulation was found to be pure. The UV 
y = 0.027x + 0.0145 
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spectrum of the ambroxol HCL in phosphate buffer 6.8 
is given in Figure: 2. 
IR ANALYSIS: 
In the spectral analysis of pure ambroxol hcl , N-H 
streching of primary amine, C-H streching , C-5 
Streching , C-H deformation , N-H out of plain bending 
of pure ambroxol HCl. The ambroxol hcl with polymer 
was almost in the same region of the wave number 
ranging from 608 cm
-1
- 3402 cm
-1
. It showed that there 
was no significant interaction between the drug and 
polymer compatible with each other. 
 
 
Figure 2: λ Max of ambroxol hydrochloride 
 
 
IR spectra of ambroxol HCl: 
 
Figure 3: IR Spectra of ambroxol hydrochloride 
 
Compatibility study of Ambroxol HCl and SCMC: 
 
Figure 4: IR Spectra of ambroxol hydrochloride and SCMC 
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Compatibility study of Ambroxol HCl and HPMC K100M  
 
Figure 5: IR Spectra of ambroxol hydrochloride and HPMC K100M 
Compatibility study of ambroxol HCl and HPMC K4M  
 
Figure 6: IR Spectra of ambroxol hydrochloride and HPMCK4M 
 
Compatibility study of ambroxol HCl and methyl cellulose: 
 
Figure 7: IR Spectra of ambroxol hydrochloride and methyl cellulose 
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Characterization of prepared medicated lollipops:  
Table 4: Appearance of medicated lollipops 
Formulation Appearance 
L0-L10 Orange, hard, little sticky, easily removed by mold 
 
 Evaluation of Ambroxol HCL medicated lollipops:  
Table 5: Standard physical tests for medicated lollipops (L0-L5) 
Formulation
 
Thickness 
(mm)±S.D 
Hardness 
(kg/cm2)±S.D 
Friability 
(%)±S.D 
Weight Variation 
(gm)±S.D 
Moisture content 
± S.D  
L0 12.6±0.33 11±0.23 0.6±0.033 5±0.41 0.5±0.02 
L1 13.2±0.32 11±0.40 0.5±0.041 4.33±0.05 0.6±0.06 
L2 12.7±0.38 10±0.40 0.7±0.012 5.09±0.06  0.8±0.023 
L3 12.9±0.14 10.5±0.23 0.56±0.044 4.99±0.04 0.4±0.012 
L4 12.1±0.31 10.7±0.12 0.74±0.061 5±0.11 0.6±0.052 
L5` 12.6±0.12 10.5±0.23 0.56±0.044 4.98±0.15 0.42±00.11 
 
Table 6: Standard physical tests for medicated lollipops (L6-L10) 
Formul
n 
Thickness(mm)±S.D Hardness 
(kg/cm2)±S.D 
Friability 
(%)±S.D 
Weight Variation 
(gm)±S.D 
Moisture content 
± S.D  
L6 12.8±0.40 11±0.23 0.67±0.057 4.88±0.05 0.5±0.02 
L7 12.5±0.12 11±0.23 0.69±0.021 4.9±0.12 0.3±0.32 
L8 12.4±0.09 10±0.23 0.78±0.057 5.05±0.44 0.4±0.0.23 
L9 12.0±0.37 11.5±0.62 0.98±0.043 5±0.1 0.5±0.025 
L10 12.6±0.33 10±0.40 0.56±0.109 4.67±1.77 0.6±0.11 
 
Lollipops of all formulations (F0 to F10) were evaluated 
for different parameters such as thickness, hardness, 
weight variation, drug content and friability and results 
are shown in 5 and 6. 
Hardness: Hardness values of the formulation ranged 
from 10-11.5 kg/cm2, which indicate good strength of 
lollipop.  
Friability: Friability values of all the formulation were 
less than 1%, indicating good strength of lollipops. . 
Weight variation: In weight variation test, the 
Pharmacopoeial limit for percent of deviation for tablets 
weighing between 5.25-4.75 is not more than 5%. The 
average percent deviation of all tablets was found to be 
within the limit and hence all formulation passes the 
weight variation test. 
Thickness: Examination of lollipops from each batch 
showed flat circular shape with no cracks having orange 
colour. The thickness of lollipops  was determined using 
Vernier caliper. The thickness of lollipops ranged from    
12-13.2 mm. All formulations showed uniform 
thickness. 
Moisture analysis: Moisture content in the given 
lollipops ranged from 0.3±0.32-0.6±0.11. 
Content uniformity: The drug content was found to be 
uniform among all formulation and ranged from 90.22 -
99.44.
 
Table 7:  Content uniformity of medicated lollipops (L0-L4) 
Batch no. L0 L1 L2 L3 L4 L5 L6 L7 L8 L9 
Drug content 
(%)±S.D 
96.99 96.52 95.65 99.44 98.23 93.22 97.66 95.45 96.74 93.34 
 
 
8.6 In-vitro drug release studies: 
The dissolution rate was studied using 100ml for 
followed by phosphate buffer (pH 6.8) for the remaining 
hours under sink condition using USP dissolution 
apparatus type II. The theoretical release profile 
calculation is important to evaluate the formulation with 
respect to release rates and to ascertain whether it 
releases the drug in predetermine manner. 
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Figure 8: In-vitro dissolution profile of L0, L1 and L2 
formulation 
     
 
Figure 9: In-vitro dissolution profile of L3, L4 and 
L5formulation 
 
 
Figure 10: In-vitro dissolution profile of L6, L7 and 
L8formulation 
 
Figure 11: In-vitro dissolution profile of L9and L10 
formulation 
 All the 11 formulation prepared were subjected to in-
vitro release study. The in-vitro method for studying the 
release rate should be so that it must simulate the mouth 
condition. In the present work in-vitro release study was 
carried out using dissolution apparatus. For different 
time interval, sample was withdrawn and cumulative 
drug release was calculated. The dissolution apparatus 
USP II paddle type was used. The temperature was 
maintained at 37± 0.5 0C and stirred at 100rpm. The 
dissolution medium being phosphate buffer of pH 6.8. 
The samples were withdrawn at 5mins interval for 
30mins. Since the drug release in the formulations F0 
were faster because this batch are without polymer. 
Cumulative percentage drug release is calculated. The 
results are given in Table 8 and Figure 8 to 12. The 
cumulative percentage drug release of L0 at the end of 
15 minutes was found to be 100.59±0.50%   at the end 
of 20 minutes. The release was faster in L0 than L1. L1, 
L2, L3 containing the methyl cellulose polymer with 
different conc. (25mg, 50mg, 75 mg). The cumulative 
percentage drug release of L1 97.65±1.00 at the end of 
20 minutes, L2 was 100.05±0.16% by the end of 25mins 
and in L3 was 100.36±0.22 at 30mins.L4, L5, L6 
containing SCMC polymer with different conc. (25, 
50,75 mg) .L4 was93.19±0.64 in 20 min. L5 was 
83.49±0.21 and L6 was 92.86 ±0.40. L7 and L8 contains 
HPMC K100polymer with two conc. (50mg,75mg) L7 
was 88.83±0.67,L8 was 89.13±0.18. L9 and L10 
containing HPMC K4M with two conc. (50mg, 75mg). 
L9 was 90.47±1.09 and L10 was 94.14±0.38. 
Hence by the determination of the in-vitro release data, 
it can be concluded that the drug release was faster in 
case of L0 without polymer. The formulations 
containing Sodium carboxy methyl cellulose and 
Hydroxy propyl methyl cellulose K4 M & K100M 
showed slower release rates when compared to M.C. 
The use of polymers showed extended release of the 
drug. Methyl cellulose (75 mg) containing lollipop gives 
the extended release up to 30 min and gives the 
100.36±0.22 cumulative% drug release 
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Table 8: Parameters studied on L3, L6, L10 formulations before and after stability study 
 
Parameters  
Before stability study After stability study 
L3 L6 L10 L3 L6 L10 
Thickness  12.9±0.14 12.8±0.40 12.6±0.33 12.9±0.14 12.8±0.40 12.6±0.33 
Hardness  10.5±0.23 11±0.23 10±0.40 10.5±0.23 11±0.23 10±0.40 
Drug content 99.44% 97.66% 98.63% 99.44% 97.66% 98.63% 
Moisture analysis  0.4±0.012 0.6±0.052 0.5±0.02 0.4±0.024 0.6±0.045 0.5±0.32 
*All the values are represents as Mean ± S. D. (n=3) 
 
Figure 12: Dissolution profile of formulations L3, L6 and L10 before and after stability study 
 
SUMMARY 
In this present study attempt was made to prepare the 
medicated lollipop for peadiatrics containing mucolytic 
and mucokinetic ambroxol HCl to enhance the release 
rate were prepared using methyl Cellulose, HPMC 
K4M, HPMC K 100M & SCMC by heating and 
congealing  method using various ratios. The obtained 
Lollipops were flat spherical and uniform in shape and 
size.The lollipops were evaluated for various 
parameters. Thickness of lollipop ranges from 12-13.2 
mm. The hardness of these lollipops ranges between 10-
11.5 kg/cm. Percentage buoyancy was in the range of 
83.59-100.56% Results of the in vitro drug release 
indicated that the ambroxol HCl released in 30 mins. 
Results of in-vitro release profile indicated that 
formulation L3, L6, and L10 were the most promising 
formulations as the extent of drug release from this 
formulation was high as compare to other formulations 
up to 30 mins. The in vitro release of medicated lollipop 
of ambroxol HCl was found in the release of drug from 
the lollipop depends on the type and concentration of 
polymer used. As per all satisfactory evaluation 
parameters, the batch L3 is found to be optimized batch. 
The stability studies showed that there was no change in 
the formulation after 90 days.by adding the various 
polymers increasing the release rate by using different 
conc. of polymers 
Thus cost effective and slow release medicated lollipop 
of ambroxol HCl in oral cavity is a safe and effective 
dosage form for pediatrics and having better 
bioavailability.  
 
CONCLUSION  
It can be concluded that medicated lollipop for 
pediatrics’ are medicated confections designed totally 
deliver drug to mouth and throat for the treatment of 
respiratory tract infection. In the study of drug and 
compatibility is concluded that the drug is compatible 
with the polymers. The various physicochemical 
properties like solubility, colour, odor, taste, pH, 
melting point are evaluated successfully. In in-vitro drug 
release analysis observed that those formulation 
containing polymers that gives better effect than without 
polymers. Formulation showed best drug release 
extended up to 30 min, compatible nature and good 
stability, so it can be a better effective formulation in 
pediatrics. Formulation showed better stability than 
other formulation. Pediatrics attracts towards this 
formulation and in dysphagia this formulation are more 
convenient. So, these novel medicated lollipops can 
make better reliability for the efficient treatment. 
.Most of the ambroxol HCl formulations are available, 
but by developing formulation we can improve stability 
of formulation, fixed dosing ,increase patient 
compliance & also bioavailability of drug. 
Future scope 
 In-vivo study 
 In-vivo in- vitro correlation 
 Formulating various formulation using different 
polymers those extended the drug release. 
 Formulating various formulation containing 
combination of drugs are used.  
Formulating this formulation for the treatment of 
various problems in paediatrics. 
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